Selecting and Sequencing Therapies to Improve Outcomes in Patients With Lymphoma

Video

Key opinion leaders describe when to refer a patient with lymphoma and at what point treatments should be switched, and the evolution of T-cell engaging therapies.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Related Content
Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

High Tumor Volume Confers CAR T-Cell Therapy Toxicity Risk in LBCL

Russ Conroy
June 30th 2025
Article

Data support incorporating volumetric PET biomarkers into toxicity risk prediction for patients receiving CAR T-cell therapy for LBCL.

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Highlighting Advancements in Personalized T-Cell Lymphoma Treatment

Viviana Cortiana, MS4;Yan Leyfman, MD
May 12th 2025
Podcast

Advances in next-generation sequencing and gene expression are reshaping T-cell lymphoma classification and the use of targeted therapies.

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

ONCOLOGY Staff
June 25th 2025
Article

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

Highlighting Insights From the Marginal Zone Lymphoma Workshop

Thomas Habermann, MD;Julie M. Vose, MD, MBA;James R. Cerhan, MD, PhD;Alexandar Tzankov, MD;Andrew D. Zelenetz, MD, PhD
February 17th 2025
Podcast

Clinicians outline the significance of the MZL Workshop, where a gathering of international experts in the field discussed updates in the disease state.

LYL314 Yields High, Durable Response Rates in Later-Line LBCL Therapy

LYL314 Yields High, Durable Response Rates in Later-Line LBCL Therapy

Tim Cortese
June 18th 2025
Article

LYL314 elicited a complete response rate of 72%, with 71% of responses lasting for 6 or more months in patients with large B-cell lymphoma in the third or later lines of therapy.

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.

Real-World Axicabtagene Ciloleucel Shows Consistent Efficacy, Safety in R/R LBCL

Courtney Flaherty
June 17th 2025
Article

A retrospective analysis of real-world data confirmed the efficacy of axi-cel in relapsed/refractory large B-cell lymphoma, with outcomes comparable to the ZUMA-7 trial.